Targeted therapies for lung cancer: clinical experience and novel agents.

ABSTRACT: Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality, the use of stereotactic radiation for early-stage tumors, the development of molecular methods to predict chemotherapy sensitivity, and genome-wide expression and mutation analysis data that have uncovered oncogene "addictions" as important therapeutic targets. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that currently includes monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The development of effective targeted therapeutics requires

SUBMITTER: Larsen JE 

PROVIDER: S-EPMC3381956 | biostudies-literature | 2011 Nov-Dec

REPOSITORIES: biostudies-literature